Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Selective ERK1/2 agonists isolated from Melia azedarach with potent anti-leukemic activity

Fig. 4

A1541, A1542 and A1543 alter phosphorylation of ERK1/2. a and b A1541–43 (0.5uM) induce phosphorylation of MAPK/ERK in HEL (a) and CB7 (b) cells, 24 h post-drug treatment. Upstream MEK phosphorylation was only slightly induced by these compounds in CB7 (b) and not at all in HEL (a) cells. c and d A1541–43 did not alter phosphorylation of PKCδ in HEL cells (c), but slightly increased PKCδ phosphorylation in CB7 cells (d). e Induction of MAPK/ERK by A1542 is not blocked by the MEK inhibitor U0126 (U), after treatment of HEL cells for 24 h with the indicated drug concentrations. However, U0126 blocksed TPA-induced phosphorylation of ERK1/2. f In HEL cells, Cedrelone (5uM) significantly reduced ERK1/2 phosphorylation induced by A1542 (0.5uM), after 24 h of drug treatment. g The compounds A1541-43 were significantly increased the expression of active unphosphorylated form of BAD, but Cedrelone in contrast reduced  its expression. Relative Density (RD)

Back to article page
\